Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FA1G5
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $41,689
Award facts
- Contract value 100% obligated
- $41,688.96 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $41,688.96 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors. This competitively awarded, non-set-aside contract utilizes firm fixed price pricing and carries an ultimate completion date of January 6, 2026. The delivery order was issued on January 5, 2026, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat moderate-to-severe eczema, asthma, and chronic rhinosinusitis, making this a critical pharmaceutical supply for military and federal healthcare systems.
This delivery order operates under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December 2026 that serves as a comprehensive global pharmaceutical support contract for military healthcare programs. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, maintains a substantial federal contracting presence supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's federal contract portfolio demonstrates consistent capability in fulfilling diverse medical supply requirements across multiple therapeutic domains, from specialty medications to vaccines and medical devices, reinforcing its role as a critical vendor in the federal medical procurement supply chain.
Quick answers
Who was awarded contract SPE2DR26FA1G5?
SPE2DR26FA1G5 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 5, 2026.
How much is contract SPE2DR26FA1G5 worth?
The government has obligated $41,689 on SPE2DR26FA1G5.
Is contract SPE2DR26FA1G5 an order under another contract?
Yes. SPE2DR26FA1G5 is a delivery order under SPE2DR25D2014, an indefinite delivery contract.
Was contract SPE2DR26FA1G5 competed?
The extent of competition for SPE2DR26FA1G5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award